Robert Lechleider Sells 55,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $22.62, for a total value of $1,244,100.00. Following the completion of the sale, the insider owned 15,805 shares in the company, valued at approximately $357,509.10. This represents a 77.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Lechleider also recently made the following trade(s):

• On Thursday, June 25th, Robert Lechleider sold 55,000 shares of Immunome stock. The stock was sold at an average price of $19.85, for a total value of $1,091,750.00.

Immunome Stock Performance

Shares of NASDAQ:IMNM traded up $0.49 on Tuesday, hitting $24.39. 1,561,508 shares of the company’s stock were exchanged, compared to its average volume of 1,438,372. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65. The company has a market capitalization of $2.76 billion, a PE ratio of -10.25 and a beta of 2.07. The firm’s 50-day moving average is $20.97 and its 200 day moving average is $21.79.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.12. On average, analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Immunome in a research report on Wednesday, May 13th. Leerink Partners dropped their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Truist Financial lifted their price target on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Barclays initiated coverage on shares of Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Institutional Investors Weigh In On Immunome

Several large investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. grew its position in shares of Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after acquiring an additional 5,003,824 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the period. Primecap Management Co. CA grew its position in Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Immunome during the 4th quarter worth $30,710,000. Finally, Sofinnova Investments Inc. increased its stake in Immunome by 271.2% in the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after purchasing an additional 1,182,426 shares during the period. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.